The 14 most recent market catalysts affecting $VRDN, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 9, 2026
Corporate Catalyst
Bullish
Impact 55
Wedbush Adjusts Price Target on Viridian Therapeutics
Wedbush Securities adjusted its price target for Viridian Therapeutics (VRDN) from $42 to $44, while maintaining an Outperform rating. This change is a direct result of the analyst…
Nov 9, 2026
Corporate Catalyst
Bullish
Impact 85
Viridian Therapeutics Announces Positive Phase 1 Results for VRDN-008
Viridian Therapeutics announced highly positive Phase 1 results for VRDN-008, an FcRn-inhibitor, indicating the drug exceeded expectations and could be best-in-class. This is a sig…
Nov 6, 2026
Corporate Catalyst
Neutral
Impact 65
Viridian Therapeutics to Host Conference Call to Present VRDN-008 Phase 1 Data and FcRn Portfolio Plans
Viridian Therapeutics is holding a conference call to present Phase 1 clinical trial data for VRDN-008 in healthy volunteers and to outline its development strategy for its FcRn po…
Nov 5, 2026
Corporate Catalyst
Neutral
Impact 60
Analyst Price Target Updates for Viridian Therapeutics
Following its third-quarter 2026 earnings, Viridian Therapeutics saw several analysts raise their price targets while maintaining 'Outperform' ratings. RBC Capital Markets, Leerink…
Nov 5, 2026
Corporate Catalyst
Bullish
Impact 60
Wells Fargo Maintains Overweight Rating and Raises Price Target for Viridian Therapeutics
Wells Fargo's decision to maintain an 'Overweight' rating and raise the price target for Viridian Therapeutics (VRDN) to $34 from $31 signals continued confidence in the company's …
Nov 5, 2026
Corporate Catalyst
Bullish
Impact 55
Wedbush Increases Price Target for Viridian Therapeutics to $42
Wedbush, an analyst firm, has raised its price target for Viridian Therapeutics (VRDN) from $41 to $42 while reiterating its 'Outperform' rating. This action signals continued conf…
Nov 5, 2026
Corporate Catalyst
Bullish
Impact 55
RBC Raises Price Target on Viridian Therapeutics to $41
RBC Capital Markets has raised its price target for Viridian Therapeutics (VRDN) to $41 from $38, while reiterating its 'Outperform' rating. This upgrade follows the company's thir…
Nov 4, 2026
Corporate Catalyst
Bullish
Impact 75
Viridian Therapeutics Reports Third Quarter 2026 Financial Results
Viridian Therapeutics announced its Q3 2026 financial results, highlighting the early success of its new thyroid eye disease (TED) treatment, Lumvoa. The product's performance has …
Nov 4, 2026
Corporate Catalyst
Bearish
Impact 75
Viridien Reports Third-Quarter 2026 Financial Results
Viridien's Q3 2026 filing reveals a mixed financial picture. While the company achieved positive net cash flow and an impressive 18% year-on-year reduction in net debt, indicating …
Sep 22, 2026
Corporate Catalyst
Bullish
Impact 55
RBC Capital Maintains Outperform on Viridian Therapeutics, Raises Price Target to $38
RBC Capital's analyst Lisa Walter maintained an 'Outperform' rating on Viridian Therapeutics and raised the price target from $36 to $38. This action signals continued bullish sent…
Aug 7, 2026
Corporate Catalyst
Bullish
Impact 55
RBC Capital Maintains Outperform on Viridian Therapeutics, Raises Price Target to $36
RBC Capital analyst Lisa Walter has reiterated an 'Outperform' rating for Viridian Therapeutics and modestly increased the price target from $35 to $36. This action signals ongoing…
Aug 7, 2026
Corporate Catalyst
Bullish
Impact 55
Truist Securities Maintains Buy on Viridian Therapeutics, Raises Price Target to $39
Truist Securities analyst Gregory Renza has maintained a 'Buy' rating on Viridian Therapeutics (VRDN) and slightly increased the price target from $38 to $39. This action indicates…
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 75
Viridian Therapeutics shares are trading higher after the company reported better-than-expected Q2 sales results.
This headline represents a significant corporate catalyst for Viridian Therapeutics. Better-than-expected sales results directly impact a company's financial health and future proj…
Aug 6, 2026
Corporate Catalyst
Bearish
Impact 85
Viridian Therapeutics Q2 EPS $(1.05) Misses $(1.02) Estimate, Sales $233.000K Beat $22.308K Estimate
Viridian Therapeutics (VRDN) reported a Q2 EPS loss of $(1.05), missing the analyst consensus of $(1.02), which is a negative signal regarding profitability. However, the company's…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.